Bevacizumab (Avastin)

Avastin (bevacizumab) is covered only for nine specified non‑oncology off‑label compendial ophthalmic indications (diabetic retinopathy; neovascular AMD; diabetic macular edema; macular edema from retinal vein occlusion; myopic choroidal neovascularization; neovascular glaucoma; retinopathy of prematurity; sickle cell neovascularization; choroidal neovascular conditions), and non‑compendial or oncology uses are excluded. Coverage requires documentation of one of the approved diagnoses, meeting applicable coverage and safety criteria, administration by or under the supervision of an ophthalmologist, and is authorized for up to 12 months (initial and renewal).

"Diabetic Retinopathy"

Sign up to see full coverage criteria, indications, and limitations.